Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 273, Issue 5 36-5, 1997, Pages

  Nauck, Michael A ^a   Niedereichholz, Ulrich ^a   Ettler, Rainer ^a   Holst, Jens Juul ^b   Ørskov, Cathrine ^b   Ritzel, Robert ^a   Schmiegel, Wolff H ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Enteroinsular axis; Glucagon like peptide 1 (7 36) amide; Incretin hormones; Pancreatic glucagon

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; HEMOGLOBIN A1C;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; NORMAL HUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; STOMACH EMPTYING;

EID: 0030667056     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1997.273.5.e981     Document Type: Article

References (16)

1. Bell, G. I., R. Sanchez-Pescador, P. J. Laybourn, and R. C. Najarian. Exon duplication and divergence in the human proglucagon gene. Nature 304: 368-371, 1983.
2. Creutzfeldt, W. The incretin concept today. Diabetologia 16: 75-85, 1975.
3. Dupré, J., M. T. Behme, I. M. Hramiak, P. McFarlane, M. P. Williamson, P. Zabel, and T. J. McDonald. Glucagon-like peptide 1 reduces postprandial glycemic excursions in IDDM. Diabetes 44: 626-630, 1995.
4. Eaton, R. P., R. C. Allen, D. S. Schade, K. M. Erickson, and J. Standefer. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behaviour. J. Clin. Endocrinol. Metab. 51: 520-528, 1980.
5. Ebert, R., J. Aschenbeck, and W. Creutzfeldt. Wirkung von humanem Gastric Inhibitory Polypeptide (GIP) auf die Magenentleerung (Abstract). Z. Gastroenterol. 27: 516, 1989.
6. Eissele, R., R. Göke, S. Willemer, H.-P. Harthus, H. Vermeer, R. Arnold, and B. Göke. Glucagon-like peptide 1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 22: 283-291, 1992.
7. George, J. D. New clinical method for measuring the rate of gastric emptying: the double sampling test meal. Gut 9: 237-242, 1968.
8. Gutniak, M. K., J. J. Holst, B. Linde, and S. Efendic. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glaecemia in NIDDM. Diabetes Care 17: 1039-1044, 1994.
9. Gutniak, M., C. Ørskov, J. J. Holst, B. Ahren, and S. Efendic. Antidiabetogenic effect of glucagon-like peptide-1 (7-36 amide) in normal subjects and patients with diabetes. N. Engl. J. Med. 326: 1316-1322, 1992.
10. Hoist, J. J. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem. J. 207: 381-388, 1982.
11. Hovorka, R., and R. H. Jones. How to measure insulin secretion? Diabetes Metab. Rev. 10: 91-117, 1994.
12. Hurwitz, A. Measuring gastric volume by dilution. Gut 22: 85-93, 1981.
13. Kalorien Mundgerecht (9th ed.). Frankfurt: Umschau Verlag, 1993.
14. Kolligs, F., H. C. Fehmann, R. Göke, and B. Göke. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19, 1995.
15. Kreymann, B., M. A. Ghatei, G. Williams, and S. R. Bloom. Glucagon-like peptide 1 (7-36): a physiological incretin in man. Lancet II: 1300-1304, 1987.
16. Layer, P., J. J. Holst, D. Grandt, and H. Goebell. Heal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig. Dis. Sci. 40: 1074-1082, 1995.